Coya Therapeutics receives $4.2M milestone from Dr. Reddy's for ALS IND acceptance

Coya Therapeutics, Inc.

FDA accepted IND for COYA 302 Phase 2 study in ALS, triggering $4.2M milestone from Dr. Reddy's Laboratories.
Additional $4.2M payment due upon first patient dosing in the Phase 2 study.
Phase 2 trial is randomized, double-blind, placebo-controlled, 24-week with 24-week open-label extension.
Milestone arises from Development and License Agreement signed December 5, 2023.
Payment signals progress in clinical development for COYA 302 combination therapy in ALS.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.